+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • ID: 4851016
  • Report
  • August 2018
  • Region: Global
  • 185 pages
  • Transparency Market Research
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now

Glaucoma Therapeutics Market: Scope and Methodology

This report analyzes the current and future prospects of the global glaucoma therapeutics market. The report comprises a comprehensive executive summary, including a market snapshot that provides overall information of various segments. The research is a combination of primary and secondary research. Primary research formed the bulk of the research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2016 to 2026, considering the macro and micro environmental factors. Growth rates for each segment within the global glaucoma therapeutics market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining the market and future opportunities has been provided in the overview section. The report also provides insights into the key trends of the glaucoma therapeutics market such as growth in geriatric and diabetic populations, increase in health care spending, and innovative drug combinations. Key market indicators influencing the global glaucoma therapeutics market, including cost constraints and regulatory landscape, have been taken into consideration. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global glaucoma therapeutics market.

Market revenue in terms of US$ Mn for the period between 2016 and 2026 along with the compound annual growth rate (CAGR %) from 2018 to 2026 are provided for all the segments, considering 2017 as the base year. The year-on-year growth of the global glaucoma therapeutics market for each segment is also reflected. Additionally, market-related factors such as favorable reimbursement scenario, gene replacement therapy, side effects associated with glaucoma drugs, and historical year-on-year growth have been taken into consideration while estimating the market size.

Glaucoma Therapeutics Market: Segmentation

Based on drug class, the global glaucoma therapeutics market has been segmented into prostaglandins, beta blockers, alpha agonists, carbonic anhydrase inhibitors, combination medications, and cholinergics. In terms of end-user, the market has been classified into hospitals, ophthalmic clinics, and ambulatory surgical centers. The hospitals segment is expected to dominate the market during the forecast period.

In terms of region, the global glaucoma therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Additionally, the regions have been divided into major countries/sub-regions. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Australia, Japan, India, Brazil, GCC Countries, South Africa, and Mexico.

Glaucoma Therapeutics Market: Competitive Landscape

The report also profiles major players in the global glaucoma therapeutics market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Allergan plc, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Santen Pharmaceuticals Co. Ltd., Valeant Pharmaceuticals International, Inc., and Aerie Pharmaceuticals, Inc.

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Glaucoma Therapeutics Market

4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Glaucoma Therapeutics Market Analysis and Forecasts, 2016-2026
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1. Value Chain Analysis
5.2. Disease Prevalence & Incidence Rate, by Region
5.3. Healthcare Industry Overview
5.4. Pipeline Analysis

6. Global Glaucoma Therapeutics Market Analysis and Forecasts, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2016-2026
6.3.1. Prostaglandins
6.3.2. Beta Blockers
6.3.3. Alpha Agonists
6.3.4. Carbonic Anhydrase Inhibitors
6.3.5. Combination Medications
6.3.6. Cholinergics
6.4. Market Attractiveness, by Drug Class

7. Global Glaucoma Therapeutics Market Analysis and Forecasts, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2016-2026
7.3.1. Hospitals
7.3.2. Ophthalmic Clinics
7.3.3. Ambulatory Surgical Centers
7.4. Market Attractiveness, by End-user

8. Global Glaucoma Therapeutics Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region

9. North America Glaucoma Therapeutics Market Analysis and Forecast
9.1. Introduction
9.2. Market Value Forecast, by Drug Class, 2016-2026
9.2.1. Prostaglandins
9.2.2. Beta Blockers
9.2.3. Alpha Agonists
9.2.4. Carbonic Anhydrase Inhibitors
9.2.5. Combination Medications
9.2.6. Cholinergics
9.3. Market Value Forecast, by End-user, 2016-2026
9.3.1. Hospitals
9.3.2. Ophthalmic Clinics
9.3.3. Ambulatory Surgical Centers
9.4. Market Value Forecast, by Country, 2016-2026
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By End-user
9.5.3. By Country

10. Europe Glaucoma Therapeutics Market Analysis and Forecast
10.1. Introduction
10.2. Market Value Forecast, by Drug Class, 2016-2026
10.2.1. Prostaglandins
10.2.2. Beta Blockers
10.2.3. Alpha Agonists
10.2.4. Carbonic Anhydrase Inhibitors
10.2.5. Combination Medications
10.2.6. Cholinergics
10.3. Market Value Forecast, by End-user, 2016-2026
10.3.1. Hospitals
10.3.2. Ophthalmic Clinics
10.3.3. Ambulatory Surgical Centers
10.4. Market Value Forecast, by Country/Sub-region, 2016-2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By End-user
10.5.3. By Country/Sub-region

11. Asia Pacific Glaucoma Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. Market Value Forecast, by Drug Class, 2016-2026
11.2.1. Prostaglandins
11.2.2. Beta Blockers
11.2.3. Alpha Agonists
11.2.4. Carbonic Anhydrase Inhibitors
11.2.5. Combination Medications
11.2.6. Cholinergics
11.3. Market Value Forecast, by End-user, 2016-2026
11.3.1. Hospitals
11.3.2. Ophthalmic Clinics
11.3.3. Ambulatory Surgical Centers
11.4. Market Value Forecast, by Country/Sub-region, 2016-2026
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By End-user
11.5.3. By Country/Sub-region

12. Latin America Glaucoma Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Market Value Forecast, by Drug Class, 2016-2026
12.2.1. Prostaglandins
12.2.2. Beta Blockers
12.2.3. Alpha Agonists
12.2.4. Carbonic Anhydrase Inhibitors
12.2.5. Combination Medications
12.2.6. Cholinergics
12.3. Market Value Forecast, by End-user, 2016-2026
12.3.1. Hospitals
12.3.2. Ophthalmic Clinics
12.3.3. Ambulatory Surgical Centers
12.4. Market Value Forecast, by Country/Sub-region, 2016-2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By End-user
12.5.3. By Country/Sub-region

13. Middle East & Africa Glaucoma Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Market Value Forecast, by Drug Class, 2016-2026
13.2.1. Prostaglandins
13.2.2. Beta Blockers
13.2.3. Alpha Agonists
13.2.4. Carbonic Anhydrase Inhibitors
13.2.5. Combination Medications
13.2.6. Cholinergics
13.3. Market Value Forecast, by End-user, 2016-2026
13.3.1. Hospitals
13.3.2. Ophthalmic Clinics
13.3.3. Ambulatory Surgical Centers
13.4. Market Value Forecast, by Country/Sub-region, 2016-2026
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By End-user
13.5.3. By Country/Sub-region

14. Competition Landscape
14.1. Market Player - Competition Matrix
14.2. Market Share Analysis, by Company (2016)
14.3. Company Profiles
14.3.1. Allergan plc
14.3.1.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2 Financial Overview
14.3.1.3 Product Portfolio
14.3.1.4 SWOT Analysis
14.3.1.5 Strategic Overview
14.3.2. Merck & Co., Inc.
14.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2 Financial Overview
14.3.2.3 Product Portfolio
14.3.2.4 SWOT Analysis
14.3.2.5 Strategic Overview
14.3.3. Novartis AG
14.3.3.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2 Financial Overview
14.3.3.3 Product Portfolio
14.3.3.4 SWOT Analysis
14.3.3.5 Strategic Overview
14.3.4. Pfizer Inc.
14.3.4.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2 Financial Overview
14.3.4.3 Product Portfolio
14.3.4.4 SWOT Analysis
14.3.4.5 Strategic Overview
14.3.5. Santen Pharmaceuticals Co. Ltd.
14.3.5.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2 Financial Overview
14.3.5.3 Product Portfolio
14.3.5.4 SWOT Analysis
14.3.5.5 Strategic Overview
14.3.6. Valeant Pharmaceuticals International, Inc.
14.3.6.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2 Financial Overview
14.3.6.3 Product Portfolio
14.3.6.4 SWOT Analysis
14.3.6.5 Strategic Overview
14.3.7. Aerie Pharmaceuticals Inc.
14.3.7.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2 Product Portfolio
14.3.7.3 SWOT Analysis
14.3.7.4 Strategic Overview
Note: Product cover images may vary from those shown
Adroll
adroll